Companies

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

Nine $1bn+ alliances were penned in December, and two exceeded $2bn.

A decade after Teva was slapped with a ten-figure fine for its alleged illegal activities blocking US generic competition to its Provigil brand, the Israeli firm has offloaded the narcolepsy drug and follow-up brand Nuvigil in the US to Apotex.

The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).

One month after announcing a pipeline pivot, Ovid Therapeutics talked to In Vivo about the importance of making strategic decisions with discipline, and the imminent neurology revolution.

Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.

In 2023, China emerged as the second largest exporter in the global biopharmaceutical pipeline. While innovation, international expansion, and commercialization remain pivotal, the industry's growth has increasingly relied on industrial efforts due to less active capital markets.

Six $1bn+ alliances were penned in November, and three exceeded $2bn.

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.